Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update
Rhea-AI Summary
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, will release its financial results for Q2 2022 on August 11, 2022, following market close. The company focuses on developing restorative therapeutics and caspase inhibitors for infectious and inflammatory diseases. Key product candidates include HST-003 for joint cartilage repair and HST-004 for spinal disc repair. Emricasan, developed with Amerimmune, targets COVID-19 and other infections. The pipeline also includes preclinical candidates CTS-2090 and CTS-2096.
Positive
- Release of Q2 2022 financial results on August 11, 2022.
- Focus on developing first-in-class restorative therapeutics.
- Collaborative development of emricasan for COVID-19 and other diseases.
Negative
- None.
News Market Reaction – HSTO
In the trading session that priced this news, HSTO gained 2.39%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen’s financial results for the second quarter ended June 30, 2022 will be released after the close of market on Thursday, August 11, 2022.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing both potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function as well as a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases. Under our biologics technology platform, our product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. In addition, within our small molecule pipeline, our product candidates include emricasan, CTS-2090 and CTS-2096. Currently, emricasan is being developed jointly with our collaboration partner, Amerimmune, for the treatment of COVID-19, and we are evaluating the use of emricasan for other infectious diseases including the treatment of MRSA. We also have preclinical product candidates, CTS-2090 and CTS-2096, novel, potent, orally bioavailable, and highly selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
